Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
Purpose. To assess neurocognitive function (NCF), psychosocial outcome, health-related quality of life (HRQoL), and long-term effects of immune-related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI). Methods. Melanoma survivors were identified within two study p...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/2192480 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547813392646144 |
|---|---|
| author | Anne Rogiers Christophe Leys Justine Lauwyck Adrian Schembri Gil Awada Julia Katharina Schwarze Jennifer De Cremer Peter Theuns Paul Maruff Mark De Ridder Jan L. Bernheim Bart Neyns |
| author_facet | Anne Rogiers Christophe Leys Justine Lauwyck Adrian Schembri Gil Awada Julia Katharina Schwarze Jennifer De Cremer Peter Theuns Paul Maruff Mark De Ridder Jan L. Bernheim Bart Neyns |
| author_sort | Anne Rogiers |
| collection | DOAJ |
| description | Purpose. To assess neurocognitive function (NCF), psychosocial outcome, health-related quality of life (HRQoL), and long-term effects of immune-related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI). Methods. Melanoma survivors were identified within two study populations (N=104), at a single-center university hospital, and defined as patients who were disease-free for at least 2 years after initiating IPI. Data were collected using 4 patient-reported outcome measures, computerized NCF testing, and a semistructured interview at the start and 1-year follow-up. Results. Out of 18 eligible survivors, 17 were recruited (5F/12M); median age is 57 years (range 33-86); and median time since initiating IPI was 5.6 years (range 2.1-9.3). The clinical interview revealed that survivors suffered from cancer-related emotional distress such as fear of recurrence (N=8), existential problems (N=2), survivor guilt (N=2), and posttraumatic stress disorder (N=6). The mean EORTC QLQ-C30 Global Score was not significantly different from the European mean of the healthy population. Nine survivors reported anxiety and/or depression (Hospitalization Depression Scale) during the survey. Seven survivors (41%) reported fatigue (Fatigue Severity Scale). Seven patients (41%) had impairment in NCF; only three out of seven survivors had impairment in subjective cognition (Cognitive Failure Questionnaire). Anxiety, depression, fatigue, and neurocognitive symptoms remained stable at the 1-year follow-up. All cases of skin toxicity (N=8), hepatitis (N=1), colitis (N=3), and sarcoidosis (N=1) resolved without impact on HRQoL. Three survivors experienced hypophysitis; all suffered from persistent fatigue and cognitive complaints 5 years after onset. One survivor who experienced a Guillain-Barré-like syndrome suffered from persisting depression, fatigue, and impairment in NCF. Conclusion. A majority of melanoma survivors treated with IPI continue to suffer from emotional distress and impairment in NCF. Timely detection in order to offer tailored care is imperative, with special attention for survivors with a history of neuroendocrine or neurological irAE. The trial is registered with B.U.N. 143201421920. |
| format | Article |
| id | doaj-art-ddd138d52a1049ddb0067bfe6a78237d |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-ddd138d52a1049ddb0067bfe6a78237d2025-02-03T06:43:32ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/21924802192480Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with IpilimumabAnne Rogiers0Christophe Leys1Justine Lauwyck2Adrian Schembri3Gil Awada4Julia Katharina Schwarze5Jennifer De Cremer6Peter Theuns7Paul Maruff8Mark De Ridder9Jan L. Bernheim10Bart Neyns11Department of Psychiatry, Centre Hospitalier Universitaire Brugmann, Brussels, BelgiumFaculty of Psychology, Université Libre de Bruxelles, Brussels, BelgiumDepartment of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, BelgiumClinical Science Department, Cogstate Ltd, Melbourne, AustraliaDepartment of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, BelgiumDepartment of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, BelgiumFaculty of Psychology and Educational Sciences, Vrije Universiteit Brussel, Brussels, BelgiumFaculty of Psychology and Educational Sciences, Vrije Universiteit Brussel, Brussels, BelgiumClinical Science Department, Cogstate Ltd, Melbourne, AustraliaDepartment of Radiotherapy, Universitair Ziekenhuis Brussel, Brussels, BelgiumEnd-of-Life Care Research Group, Faculty of Medicine, Vrije Universiteit Brussel, Brussels, BelgiumDepartment of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, BelgiumPurpose. To assess neurocognitive function (NCF), psychosocial outcome, health-related quality of life (HRQoL), and long-term effects of immune-related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI). Methods. Melanoma survivors were identified within two study populations (N=104), at a single-center university hospital, and defined as patients who were disease-free for at least 2 years after initiating IPI. Data were collected using 4 patient-reported outcome measures, computerized NCF testing, and a semistructured interview at the start and 1-year follow-up. Results. Out of 18 eligible survivors, 17 were recruited (5F/12M); median age is 57 years (range 33-86); and median time since initiating IPI was 5.6 years (range 2.1-9.3). The clinical interview revealed that survivors suffered from cancer-related emotional distress such as fear of recurrence (N=8), existential problems (N=2), survivor guilt (N=2), and posttraumatic stress disorder (N=6). The mean EORTC QLQ-C30 Global Score was not significantly different from the European mean of the healthy population. Nine survivors reported anxiety and/or depression (Hospitalization Depression Scale) during the survey. Seven survivors (41%) reported fatigue (Fatigue Severity Scale). Seven patients (41%) had impairment in NCF; only three out of seven survivors had impairment in subjective cognition (Cognitive Failure Questionnaire). Anxiety, depression, fatigue, and neurocognitive symptoms remained stable at the 1-year follow-up. All cases of skin toxicity (N=8), hepatitis (N=1), colitis (N=3), and sarcoidosis (N=1) resolved without impact on HRQoL. Three survivors experienced hypophysitis; all suffered from persistent fatigue and cognitive complaints 5 years after onset. One survivor who experienced a Guillain-Barré-like syndrome suffered from persisting depression, fatigue, and impairment in NCF. Conclusion. A majority of melanoma survivors treated with IPI continue to suffer from emotional distress and impairment in NCF. Timely detection in order to offer tailored care is imperative, with special attention for survivors with a history of neuroendocrine or neurological irAE. The trial is registered with B.U.N. 143201421920.http://dx.doi.org/10.1155/2020/2192480 |
| spellingShingle | Anne Rogiers Christophe Leys Justine Lauwyck Adrian Schembri Gil Awada Julia Katharina Schwarze Jennifer De Cremer Peter Theuns Paul Maruff Mark De Ridder Jan L. Bernheim Bart Neyns Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab Journal of Immunology Research |
| title | Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab |
| title_full | Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab |
| title_fullStr | Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab |
| title_full_unstemmed | Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab |
| title_short | Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab |
| title_sort | neurocognitive function psychosocial outcome and health related quality of life of the first generation metastatic melanoma survivors treated with ipilimumab |
| url | http://dx.doi.org/10.1155/2020/2192480 |
| work_keys_str_mv | AT annerogiers neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT christopheleys neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT justinelauwyck neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT adrianschembri neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT gilawada neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT juliakatharinaschwarze neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT jenniferdecremer neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT petertheuns neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT paulmaruff neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT markderidder neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT janlbernheim neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab AT bartneyns neurocognitivefunctionpsychosocialoutcomeandhealthrelatedqualityoflifeofthefirstgenerationmetastaticmelanomasurvivorstreatedwithipilimumab |